利伐沙班在国内上市时间

It is the world's first highly selective oral anticoagulant that directly inhibits Factor

In June 2009, rivaroxaban was officially launched in China under the trade name Xarelto and is used to prevent or reduce the formation of blood clots, deep vein thrombosis (DVT) and pulmonary embolism (PE) after hip or knee replacement surgery.

Rivaroxaban administration: Orally. Rivaroxaban 10mg can be taken with food or alone.

Rivaroxaban 15 mg or 20 mg tablets should be taken with food.

To prevent venous thrombosis in adults undergoing elective hip or knee replacement surgery:

The recommended dose is rivaroxaban 10 mg orally once daily. If the wound has stopped bleeding, the first dose of medication should be between 6 and 10 hours after surgery.

For patients undergoing major hip surgery, the recommended course of treatment is 35 days.

For patients undergoing major knee surgery, the recommended course of treatment is 12 days.

If a missed dose occurs, the patient should take rivaroxaban immediately and continue taking the dose once daily the next day.

Treat DVT and reduce the risk of acute DVT recurrence and PE

The recommended dose for initial treatment of acute DVT is 15 mg twice daily for the first three weeks, followed by 20 mg once daily for maintenance treatment and to reduce the risk of recurrent DVT and PE.

It is an anticoagulant drug and a new type of oral anticoagulant that has an inhibitory effect on coagulation factor X. There is no need to monitor coagulation, it has a relatively long action time, and reduces the risk of bleeding for patients. It is a very safe drug, and its clinical efficacy is very reliable.